Epigenomics: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States

22-Jul-2010 - USA

Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA methylation technologies non-exclusively licensed to ARUP in August 2009.

According to ARUP the independently developed and validated Septin9 test identifies nine out of ten people with previously undetected colorectal cancer, including those with early stage disease. ARUP states that the test, which is now available to physicians and patients in the U.S., is not meant to replace colonoscopy but primarily aims at patients who cannot or will not undergo the established screening methods.

Other news from the department research and development

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy